Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Mobility exercises are an important part of fitness as we age. Here are some tips- Philippines evacuates 3,000 villagers after volcano activity raises alert level
- Monetary Security: Building Serious areas of strength for an Establishment
- The Fate of Gaming: 5 Energizing Advancements Not too far off
- An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- Embrace the Outside: Exercises and Entertainment
- Belarusian parliament passes a bill to crack down on LGBTQ+ rights
- Baidu robotaxi outage in Wuhan caused by 'system failure', police say
- Russia patents space station designed to generate artificial gravity
